BlackThorn Therapeutics Announces Positive Phase 1 Results for Its Selective KOR Antagonist, BTRX-335140 by bizlift | Apr 1, 2019 | BlackThorn Press Releases
BlackThorn Therapeutics Announces R&D Updates by bizlift | Jan 4, 2019 | BlackThorn Press Releases, Portfolio News
BlackThorn Therapeutics Names Bill Martin, Ph.D., President and Chief Operating Officer by bizlift | Nov 5, 2018 | BlackThorn Press Releases, Portfolio News
BlackThorn Therapeutics Announces Participation in Key Data Science and Cloud Computing Panels to Advance Therapeutic Development at 2018 BIO Investor Forum by bizlift | Oct 11, 2018 | BlackThorn Press Releases, Portfolio News
BlackThorn Therapeutics Announces Exclusive Licensing Agreement and Extension of Key Collaboration with Yale University by bizlift | Aug 6, 2018 | BlackThorn Press Releases, Portfolio News
